Viewing posts categorised under: Press Release

AZTherapies, Inc. appoints Karen Reeves, MD as President and Chief Medical Officer

Posted by bwg in Press Release | 0 comments

BOSTON, Oct. 31, 2017 /CNW/ -- Former Pfizer executive joins AZTherapies focused on Alzheimer's Disease, ischemic stroke, and other neurological diseases by creating novel treatments for neurodegeneration and neuroinflammation. AZTherapies, Inc. is a privately held advanced clinical stage pharmaceutical company located in Boston, MA that is developing breakthrough treatments for Alzheimer's disease, ischemic stroke, and other neurological diseases associated with neurodegeneration and neuroinflammation. The lead product candidate, a combination therapy treatment of two re-engineered drugs, ALZT-OP1, is being studied in a Phase 3 Early Alzheimer's clinical trial, the COGNITE trial.  

AZTherapies Commences Phase III Pivotal Trial – for ALZT-OP1 in Early Alzheimer’s Disease

Posted by bwg in Press Release | 0 comments

AZTherapies Commences Phase III Pivotal Trial - for ALZT-OP1 in Early Alzheimer's Disease BOSTON, Sept. 15, 2015 /PRNewswire/ -- AZTherapies, Inc. a company developing a novel combination therapy for Alzheimer's disease based on technology licensed from Massachusetts General Hospital, announced that it is commencing a Phase III clinical study for early Alzheimer's disease, after having received a SPA (Special Protocol Assessment) agreement notice from US Food and Drug Administration (FDA).  

AZTherapies cleared to start enrolling under their IND for a Phase III clinical efficacy study for ALZT-OP1 in early Alzheimer’s disease

Posted by bwg in Press Release | 0 comments

AZTherapies cleared to start enrolling under their IND for a Phase III clinical efficacy study for ALZT-OP1 in early Alzheimer's disease BOSTON, Mass., May 23, 2014 /PRNewswire/ -- AZTherapies, Inc. a company developing novel treatments for Alzheimer's disease based on technology licensed from Massachusetts General Hospital, announced that it has received notice from FDA that it may proceed with the Phase III clinical study submitted in its IND application. This study is for its lead program, ALZT-OP1, a novel combination therapy for the prevention and treatment of early Alzheimer's disease.